143 related articles for article (PubMed ID: 38481366)
1. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.
De Sa H; Maziarz RT; Gandhi AP
Expert Opin Biol Ther; 2024 Mar; 24(3):139-146. PubMed ID: 38481366
[TBL] [Abstract][Full Text] [Related]
2. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
3. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation.
de Koning C; Tao W; Lacna A; van Veghel K; Horwitz ME; Sanz G; Jagasia MH; Wagner JE; Stiff PJ; Hanna R; Cilloni D; Valcárcel D; Peled T; Galamidi Cohen E; Goshen U; Pandit A; Lindemans CA; Jan Boelens J; Nierkens S
Bone Marrow Transplant; 2021 Nov; 56(11):2826-2833. PubMed ID: 34312498
[TBL] [Abstract][Full Text] [Related]
4. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz ME; Stiff PJ; Cutler C; Brunstein C; Hanna R; Maziarz RT; Rezvani AR; Karris NA; McGuirk J; Valcarcel D; Schiller GJ; Lindemans CA; Hwang WYK; Koh LP; Keating A; Khaled Y; Hamerschlak N; Frankfurt O; Peled T; Segalovich I; Blackwell B; Wease S; Freedman LS; Galamidi-Cohen E; Sanz G
Blood; 2021 Oct; 138(16):1429-1440. PubMed ID: 34157093
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
Parikh S; Brochstein JA; Galamidi E; Schwarzbach A; Kurtzberg J
Blood Adv; 2021 Feb; 5(3):843-852. PubMed ID: 33560399
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Lin C; Sajeev G; Stiff PJ; Brunstein CG; Cutler C; Sanz G; Lindemans CA; Rezvani AR; Hanna R; Koh LP; Maziarz RT; Hwang WYK; Song Y; Liu Q; Manghani R; Sivaraman S; Signorovitch J; Horwitz ME; Sung AD
Transplant Cell Ther; 2023 Jan; 29(1):52.e1-52.e9. PubMed ID: 36179986
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial.
Majhail NS; Miller B; Dean R; Manghani R; Shin H; Sivaraman S; Maziarz RT
Transplant Cell Ther; 2023 Dec; 29(12):749.e1-749.e5. PubMed ID: 37703995
[TBL] [Abstract][Full Text] [Related]
9. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U
Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
11. A new beginning: can omidubicel emerge as the next, viable alternative donor source?
Gandhi AP; Newell LF; Maziarz RT
Ther Adv Hematol; 2023; 14():20406207231192146. PubMed ID: 37664800
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.
Gómez-Santos C; González-Vicent M; Molina B; Deltoro N; Herrero B; Ruiz J; Pérez-Martínez A; Diaz MA
World J Pediatr; 2021 Dec; 17(6):609-618. PubMed ID: 34590210
[TBL] [Abstract][Full Text] [Related]
13. Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood.
Oshrine BR; Li Y; Teachey DT; Heimall J; Barrett DM; Bunin N
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1581-9. PubMed ID: 23939199
[TBL] [Abstract][Full Text] [Related]
14. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
Bhatt ST; Bednarski JJ
Front Immunol; 2020; 11():1988. PubMed ID: 33013851
[TBL] [Abstract][Full Text] [Related]
15. Increasing Stem Cell Dose Promotes Posttransplant Immune Reconstitution.
Xu N; Shen S; Dolnikov A
Stem Cells Dev; 2017 Apr; 26(7):461-470. PubMed ID: 27998208
[TBL] [Abstract][Full Text] [Related]
16. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections.
Dumont-Lagacé M; Li Q; Tanguay M; Chagraoui J; Kientega T; Cardin GB; Brasey A; Trofimov A; Carli C; Ahmad I; Bambace NM; Bernard L; Kiss TL; Roy J; Roy DC; Lemieux S; Perreault C; Rodier F; Dufresne SF; Busque L; Lachance S; Sauvageau G; Cohen S; Delisle JS
Transplant Cell Ther; 2021 Jan; 27(1):76.e1-76.e9. PubMed ID: 33022376
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.
Shi PA; Luchsinger LL; Greally JM; Delaney CS
Curr Opin Hematol; 2022 Nov; 29(6):317-326. PubMed ID: 36066376
[TBL] [Abstract][Full Text] [Related]
19. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Yu ZP; Ding JH; Sun AN; Chen BA; Ge Z; Wu DP
Stem Cells Dev; 2019 Oct; 28(20):1376-1383. PubMed ID: 31464164
[TBL] [Abstract][Full Text] [Related]
20. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.
Bejanyan N; Brunstein CG; Cao Q; Lazaryan A; Luo X; Curtsinger J; Mehta RS; Warlick E; Cooley SA; Blazar BR; Miller JS; Weisdorf D; Wagner JE; Verneris MR
Blood Adv; 2018 Apr; 2(8):909-922. PubMed ID: 29678809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
